Scarica l'app Stockscreener
12.10
3.01%
-0.375
Dopo l'orario di chiusura:
12.11
0.010
+0.08%
Precedente Chiudi:
$12.47
Aprire:
$12.15
Volume 24 ore:
393.41K
Relative Volume:
1.23
Capitalizzazione di mercato:
$310.79M
Reddito:
-
Utile/perdita netta:
$11.77M
Rapporto P/E:
20.92
EPS:
0.5785
Flusso di cassa netto:
$-19.23M
1 W Prestazione:
-7.77%
1M Prestazione:
-17.41%
6M Prestazione:
-55.97%
1 anno Prestazione:
-39.23%
Intervallo 1D:
$11.56
$12.55
Intervallo di 1 settimana:
$11.56
$13.40
Portata 52W:
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
Nome
Tourmaline Bio Inc
Settore
Industria
Telefono
646-481-9832
Indirizzo
27 WEST 24TH STREET, NEW YORK
Confronta TRML con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
12.10 | 310.79M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.49 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.39 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
546.22 | 33.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
226.28 | 29.29B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
208.31 | 22.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-06 | Iniziato | Wedbush | Outperform |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-11-11 | Reiterato | H.C. Wainwright | Buy |
| 2023-12-15 | Iniziato | Jefferies | Buy |
| 2023-12-04 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-17 | Iniziato | Truist | Buy |
| 2023-10-31 | Iniziato | Guggenheim | Buy |
| 2023-10-25 | Iniziato | Piper Sandler | Overweight |
| 2022-10-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mostra tutto
Tourmaline Bio Inc Borsa (TRML) Ultime notizie
Truist Cuts Price Target on Tourmaline Bio to $63 From $74, Keeps Buy Rating - MarketScreener
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Rating of “Buy” by Brokerages - Defense World
Talaris Therapeutics stock hits 52-week low at $11.85 By Investing.com - Investing.com Canada
Prudential Financial Inc. Cuts Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data - Seeking Alpha
Should You Invest in H&R Block Inc (HRB) Now? - News Heater
Swiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leading Factor Driving the Thyroid Eye Disease (TED) Market in 2025: Thyroid Disorders And Their Influence ... - WhaTech
ProfittoPath - TradingView
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Sold by AlphaQuest LLC - Defense World
Tourmaline Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Tourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, Wedbush Analyst Says - Defense World
HC Wainwright Raises Tourmaline Bio (NASDAQ:TRML) Price Target to $50.00 - Defense World
H.C. Wainwright raises Tourmaline Bio stock target to $50 By Investing.com - Investing.com Canada
Tourmaline Bio price target raised to $43 from $42 at Wedbush - TipRanks
H.C. Wainwright raises Tourmaline Bio stock target to $50 - Investing.com India
Wedbush Lifts Price Target on Tourmaline Bio to $43 From $42, Keeps Outperform Rating - Marketscreener.com
Novo Nordisk (0QIU) Gets a Buy from UBS - The Globe and Mail
Tourmaline Bio’s 2024 Financial Results and Strategic Advances - TipRanks
Tourmaline Bio shares fall as Q4 loss widens - Investing.com
Tourmaline Bio shares fall as Q4 loss widens By Investing.com - Investing.com UK
TOURMALINE BIO Earnings Results: $TRML Reports Quarterly Earnings - Nasdaq
Tourmaline Bio, Inc. SEC 10-K Report - TradingView
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Tourmaline Bio's cash position to provide cash runway into second half of 2027 -March 13, 2025 at 07:39 am EDT - Marketscreener.com
Tourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial Outlook - Nasdaq
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business - Bluefield Daily Telegraph
Tourmaline Bio Secures 2.5-Year Cash Runway with $294M, Accelerates Key Clinical Trials - StockTitan
Tourmaline Bio (TRML) Projected to Post Earnings on Tuesday - Defense World
Wedbush Forecasts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio (NASDAQ:TRML) Research Coverage Started at Wedbush - Defense World
Rhumbline Advisers Has $722,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio rises as Wedbush initiates with Outperform - MSN
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - NewsBreak
Wedbush bullish on Tourmaline Bio, initiates with an Outperform - TipRanks
Wedbush Initiates Coverage on Tourmaline Bio With Outperform Rating, $42 Price Target - Marketscreener.com
Wedbush Initiates Tourmaline Bio at Outperform With $42 Price Target -March 06, 2025 at 07:22 am EST - Marketscreener.com
Robinhood initiated, MongoDB downgraded: Wall Street's top analyst calls - Yahoo Finance
We Tested Over 25 Curling Irons. These 13 Are the Best - MarieClaire.com
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Volatus Aerospace and Draganfly Expand Collaboration to Service High-Value Geospatial Power Utility Customers - The Manila Times
3 Reasons to Buy American Express Stock Like There's No Tomorrow - The Globe and Mail
When and Where to Catch Tourmaline Bio's Next Investor Presentation - StockTitan
Brokers Set Expectations for Tourmaline Bio FY2024 Earnings - MarketBeat
Truist maintains $74 target on Tourmaline Bio stock, reiterates buy By Investing.com - Investing.com UK
Lifesci Capital Predicts Tourmaline Bio FY2024 Earnings - Defense World
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
Lifesci Capital Initiates Coverage on Tourmaline Bio (NASDAQ:TRML) - Armenian Reporter
Tourmaline Bio (NASDAQ:TRML) Coverage Initiated by Analysts at Lifesci Capital - Defense World
Tourmaline Bio Inc Azioni (TRML) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.35%
10.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):